atogepant + ubrogepant

**Atogepant + ubrogepant** is a combination of two oral small molecule CGRP (calcitonin gene-related peptide) receptor antagonists, both used in the treatment of migraine. Atogepant is approved for the preventive treatment of episodic or chronic migraine, while ubrogepant is used for the acute treatment of migraine attacks. Both drugs function by blocking the CGRP receptor, thereby inhibiting CGRP-mediated nociception, vasodilation, and neurogenic inflammation involved in migraine pathophysiology. Clinical studies have shown that the combination is safe and well tolerated, with no clinically meaningful pharmacokinetic interactions or new safety signals reported for the combination versus individual agents in adults with history of migraine[1][3][5][7].

Brand names

none known for the combination

Other names

none known for the combination